Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Long-awaited results from the ANCHOR study suggest screening to detect precancerous lesions should be part of routine care.
A majority people with oral and throat cancer tested positive for DNA from high-risk HPV types in their saliva.
Teens can receive the cancer-preventing HPV vaccine at the same time as their COVID-19 vaccine.
The National Comprehensive Cancer Network publishes a new guide that includes updated patient guidelines for colon and rectal cancers.
The early cancer is detected, the easier it is to treat.
However, other malignancies caused by human papillomavirus, including anal and oral cancers, are on the rise.
While researchers try to figure out whether treating early anal tissue changes can prevent cancer, some are investigating treatments.
A study comparing matched groups of people with and without HIV found that smoking was a powerful cancer risk factor, especially for women.
“People living with HIV shoulder an enormous burden of cancer,” said lead researcher Joseph Sparano, MD.
Pomalyst led to resolution of anal precancer in men with or without HIV.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
Study finds that routine screening reduces anal cancer rate among people with HIV.
Keytruda may prolong survival compared with standard therapy.
More widespread vaccination could reduce cervical, anal, oral and other cancers caused by human papillomavirus.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
Abnormal anal screening results are common, but they often do not to lead to invasive cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.